Polycystic Kidney Diseases
Recent clinical, regulatory, research and industry developments relating to this disease.
Immune checkpoint activity regulates polycystic kidney disease progression.
What's happening now
An analyst briefing on current research, clinical, regulatory and industry activity surrounding this disease.
Clinical trials
The current development programme across all trial phases.
Research activity
Key research shaping understanding of this disease, combining the latest publications with the most influential evidence.
Major themes2
- Polycystic Kidney Diseases1
- Polycystic Kidney, Autosomal Dominant1
Leading journals1
- JCI insight1
Leading researchers8
- Bauer CD1
- Berger MD1
- Chonchol MB1
- Clambey ET1
- Furgeson SB1
- Gitomer BY1
- Hopp K1
- Kleczko EK1
Affiliations (unnormalised)2
- University of Colorado Anschutz Medical Campus1
- University of Oklahoma Health Sciences Center1
Associated genes
Genes associated with this disease in the canonical knowledge graph (Open Targets evidence). Number shows the association score.
Reference
Authoritative identity, definition & identifiers.
Hereditary diseases that are characterized by the progressive expansion of a large number of tightly packed CYSTS within the KIDNEYS. They include diseases with autosomal dominant and autosomal recessive inheritance.
- Disease identity & definition — NLM Medical Subject Headings (MeSH), public domain
- Clinical trials — ClinicalTrials.gov (U.S. National Library of Medicine)
- Research activity — Europe PMC (EMBL-EBI) + OpenAlex-derived paper links
- Related entities are derived from literature co-mention (studied together) — associative, not causal.